AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29498885 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery (skin incision and exposure of the ECRB alone; n = 13)
Number of subjects: 26
Study 27642077 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI (citalopram, 40mg)
Number of subjects: 18
Study 27642077 — intervention group
Group type: EXPERIMENTAL
Intervention: NK1R antagonist (GR205171, 5mg)
Number of subjects: 18
Study 27642077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24290749 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous hepatic perfusion (PHP) with venovenous bypass circuit and hemofiltration, receiving hepatic intra-arterial melphalan, 3 mg/kg for 30 minutes with 60 minutes of hemofiltration
Number of subjects: 5
Study 24290749 — intervention group
Group type: COMPARATOR
Intervention: Best alternative care (BAC)
Number of subjects: 5
Study 21283045 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-system suctioning
Number of subjects: 250
Study 21283045 — intervention group
Group type: COMPARATOR
Intervention: Open endotracheal suctioning
Number of subjects: 250
Study 21283045 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ventilator-associated pneumonia
Number of subjects: 250
Study 21283045 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without ventilator-associated pneumonia
Number of subjects: 250
Study 20674364 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-paretic leg constraint by a step
Number of subjects: 13
Study 20674364 — intervention group
Group type: COMPARATOR
Intervention: Normal seat height (100% of knee height)
Number of subjects: 13
Study 20674364 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated seat height (130% of knee height)
Number of subjects: 13
Study 17462454 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and perioperative blood conservation interventions
Number of subjects: 0
Study 17462454 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrinolytic drugs
Number of subjects: 0
Study 17462454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-saving device
Number of subjects: 0
Study 17462454 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality blood conservation program
Number of subjects: 0
Study 17462454 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 0
Study 17462454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative blood salvage
Number of subjects: 0
Study 17462454 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous predonation and normovolemic hemodilution
Number of subjects: 0
Study 17462454 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus, institution-specific blood transfusion algorithms
Number of subjects: 0
Study 15060495 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated pulpal pressure with Superbond C&B adhesive luting agent
Number of subjects: 48
Study 15060495 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated pulpal pressure with polycarboxylate luting cement (Poly-F Plus)
Number of subjects: 48
Study 15060495 — intervention group
Group type: COMPARATOR
Intervention: No simulated pulpal pressure with Superbond C&B adhesive luting agent
Number of subjects: 48
Study 15060495 — intervention group
Group type: COMPARATOR
Intervention: No simulated pulpal pressure with polycarboxylate luting cement (Poly-F Plus)
Number of subjects: 48
Study 11521696 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term topical prednisolone acetate 1% (0-6 months)
Number of subjects: 136
Study 11521696 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term topical prednisolone acetate 1% (0-12 months)
Number of subjects: 136
Study 9988360 — intervention group
Group type: EXPERIMENTAL
Intervention: CATS‐Fresenius
Number of subjects: 27
Study 9988360 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequestra 1000‐Medtronic
Number of subjects: 27
Study 9988360 — intervention group
Group type: COMPARATOR
Intervention: Blood products from institutional blood bank
Number of subjects: 27
Study 7921461 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic CPAP
Number of subjects: 19
Study 7921461 — intervention group
Group type: COMPARATOR
Intervention: Assisted Spontaneous Breathing (ASB)
Number of subjects: 19
Study 3260795 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid block and light general anaesthesia
Number of subjects: 98
Study 3260795 — intervention group
Group type: COMPARATOR
Intervention: Conventional general anaesthesia with intermittent positive pressure ventilation
Number of subjects: 98
Study 30341095 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (400 μg) and vitamin B12 (500 μg) supplementation
Number of subjects: 2524
Study 30341095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2524
Study 30082325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 1791
Study 30082325 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 1791
Study 30082325 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c measures
Number of subjects: 1791
Study 26813674 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-PACK programme
Number of subjects: 31411
Study 26813674 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31411
Study 25168768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of tetanus-diphtheria vaccine
Number of subjects: 230
Study 25168768 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of tetanus-diphtheria vaccine
Number of subjects: 230
Study 22542789 — intervention group
Group type: EXPERIMENTAL
Intervention: Echovist(®) at body temperature
Number of subjects: 0
Study 22542789 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile saline at body temperature
Number of subjects: 0
Study 22542789 — intervention group
Group type: COMPARATOR
Intervention: Echovist(®) at room temperature
Number of subjects: 0
Study 22542789 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline at room temperature
Number of subjects: 0
Study 19188547 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-guided TBNA
Number of subjects: 50
Study 19188547 — intervention group
Group type: COMPARATOR
Intervention: Standard 19-gauge TBNA
Number of subjects: 50
Study 17468196 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (sustanon 200 mg)
Number of subjects: 20
Study 17468196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16055865 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 167
Study 12082326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure controlled inverse ratio ventilation (PC‐IRV)
Number of subjects: 0
Study 12082326 — intervention group
Group type: COMPARATOR
Intervention: High PEEP (15 cm H2O) and usual I:E ratio (1:2)
Number of subjects: 0
Study 10511068 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg) three times a day with meals for 1 year
Number of subjects: 75
Study 10511068 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times a day with meals for 1 year
Number of subjects: 75
Study 7589043 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg.day-1 bezafibrate
Number of subjects: 26
Study 7589043 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg.day-1 bezafibrate
Number of subjects: 26
Study 7589043 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (probucol + bezafibrate)
Number of subjects: 26
Study 7589043 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol concentration
Number of subjects: 26
Study 7589043 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP mass
Number of subjects: 26
Study 2179351 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programme including an information booklet
Number of subjects: 45
Study 2179351 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 84263 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (1 mg/kg intramuscularly or 1 mg/kg orally)
Number of subjects: 11
Study 84263 — intervention group
Group type: COMPARATOR
Intervention: Control (no chlorpromazine)
Number of subjects: 11
Study 30987526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear protection during water exposure (ear plugs and headbands, n = 130)
Number of subjects: 244
Study 30987526 — intervention group
Group type: COMPARATOR
Intervention: No ear protection (n = 114)
Number of subjects: 244
Study 30987526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear protection during water exposure
Number of subjects: 244
Study 30987526 — intervention group
Group type: COMPARATOR
Intervention: No ear protection
Number of subjects: 244
Study 30987526 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 244
Study 28303842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinaverium bromide (100 mg, three times a day) one day before examination combined with scopolamine butylbromide (20 mg) 10 min before colonoscopy (Group A)
Number of subjects: 1000
Study 28303842 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium bromide alone on the day of colonoscopy (100 mg, three times a day) (Group B0)
Number of subjects: 1000
Study 28303842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinaverium bromide alone one day before colonoscopy (100 mg, three times a day) (Group B1)
Number of subjects: 1000
Study 28303842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinaverium bromide alone two days before colonoscopy (100 mg, three times a day) (Group B2)
Number of subjects: 1000
Study 28303842 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine butylbromide alone (20 mg) before colonoscopy (Group C)
Number of subjects: 1000
Study 25456093 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (Suboxone)
Number of subjects: 80
Study 25456093 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 80
Study 25456093 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued Methadone
Number of subjects: 80
Study 25456093 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboxone
Number of subjects: 80
Study 25726210 — intervention group
Group type: EXPERIMENTAL
Intervention: Chia flour (35 g/day)
Number of subjects: 26
Study 25726210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22995877 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aggressive (EA) strategy (coronary angiography and, when indicated, revascularization within 72 h)
Number of subjects: 313
Study 22995877 — intervention group
Group type: COMPARATOR
Intervention: Initially conservative (IC) strategy (angiography and revascularization only for recurrent ischemia)
Number of subjects: 313
Study 22995877 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aggressive (EA) strategy
Number of subjects: 313
Study 19091409 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation at high-risk prethreshold ROP (early treated - ET)
Number of subjects: 401
Study 19091409 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (CM)
Number of subjects: 401
Study 17304128 — intervention group
Group type: EXPERIMENTAL
Intervention: Curare during anesthesia
Number of subjects: 20
Study 17304128 — intervention group
Group type: COMPARATOR
Intervention: No curare during anesthesia (Control)
Number of subjects: 20
Study 15310350 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral celecoxib 200 mg
Number of subjects: 60
Study 15310350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12406587 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 g elderberry concentrate (containing 1.9 g of anthocyanins) diluted with water
Number of subjects: 16
Study 12406587 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 g elderberry concentrate (containing 1.9 g of anthocyanins) diluted with 30 g sucrose
Number of subjects: 16
Study 9832096 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose isoproterenol (3- and 5-microg/min)
Number of subjects: 160
Study 9832096 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.4 mg)
Number of subjects: 160
Study 9832096 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (after drug-free state)
Number of subjects: 160
Study 9832096 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose isoproterenol infusion and nitroglycerin
Number of subjects: 160
Study 9832096 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 160
Study 9832096 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study 7661125 — intervention group
Group type: EXPERIMENTAL
Intervention: High meat diet (HM)
Number of subjects: 14
Study 7661125 — intervention group
Group type: COMPARATOR
Intervention: Low meat diet (LM)
Number of subjects: 14
Study 7661125 — intervention group
Group type: COMPARATOR
Intervention: Low meat with mineral supplements diet (LS)
Number of subjects: 14
Study 2788004 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated sodium salicylate 4.8 g daily
Number of subjects: 18
Study 2788004 — intervention group
Group type: COMPARATOR
Intervention: Enteric coated aspirin 4.8 g daily
Number of subjects: 18
Study 388397 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid (250 mg, increased to 500 mg if warranted)
Number of subjects: 66
Study 388397 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg, increased to 100 mg if warranted)
Number of subjects: 66
Study 31488049 — intervention group
Group type: EXPERIMENTAL
Intervention: SamPler, a semi-automated method for gene functional annotation
Number of subjects: 0
Study 28915304 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine initiation in 2010
Number of subjects: 0
Study 28915304 — intervention group
Group type: COMPARATOR
Intervention: HPV vaccine initiation in 2008
Number of subjects: 0
Study 28915304 — intervention group
Group type: COMPARATOR
Intervention: HPV vaccine initiation in 2009
Number of subjects: 0
Study 28915304 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine completion in 2010
Number of subjects: 0
Study 28915304 — intervention group
Group type: COMPARATOR
Intervention: HPV vaccine completion in 2008
Number of subjects: 0
Study 28915304 — intervention group
Group type: COMPARATOR
Intervention: HPV vaccine completion in 2009
Number of subjects: 0
Study 26294061 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 0.2 mA
Number of subjects: 29
Study 26294061 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 0.5 mA
Number of subjects: 29
Study 26294061 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 1 mA
Number of subjects: 29
Study 26294061 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 2 mA
Number of subjects: 29
Study 26294061 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability for 0.5 mA
Number of subjects: 29
Study 26294061 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response to tDCS
Number of subjects: 29
Study 23379490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alfacalcidol once weekly
Number of subjects: 29
Study 16954519 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 147
Study 15458450 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg and 80 mg daily)
Number of subjects: 2102
Study 15458450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2102
Study 10657833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide therapy (IVCY) for 36 months
Number of subjects: 16
Study 8841155 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg taken simultaneously with triazolam
Number of subjects: 10
Study 8841155 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg taken 3 hours before triazolam
Number of subjects: 10
Study 8841155 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg taken 12 hours before triazolam
Number of subjects: 10
Study 8841155 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg taken 24 hours before triazolam
Number of subjects: 10
Study 8841155 — intervention group
Group type: COMPARATOR
Intervention: Triazolam without itraconazole
Number of subjects: 10
Study 1360474 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0
Study 1360474 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 0
Study 6099589 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 30
Study 6099589 — intervention group
Group type: COMPARATOR
Intervention: ACTH 4-9 analog
Number of subjects: 30
Study 6099589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31434161 — intervention group
Group type: EXPERIMENTAL
Intervention: Barcode-assisted medication administration (BCMA) system
Number of subjects: 4
Study 31434161 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BCMA system)
Number of subjects: 4
Study 29798256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium Chloride Buccal Tablets
Number of subjects: 60
Study 29798256 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 26362487 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM at 33°C
Number of subjects: 171
Study 26362487 — intervention group
Group type: COMPARATOR
Intervention: TTM at 36°C
Number of subjects: 171
Study 23886754 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 22
Study 23886754 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH treatment initially)
Number of subjects: 22
Study 21276660 — intervention group
Group type: EXPERIMENTAL
Intervention: Early excision and grafting (E&G)
Number of subjects: 40
Study 21276660 — intervention group
Group type: COMPARATOR
Intervention: Delayed skin grafting
Number of subjects: 40
Study 19601507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 16
Study 19601507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16412989 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin therapy (oral folic acid, B‐12, and pyridoxine) for 3 months
Number of subjects: 42
Study 16412989 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 42
Study 12633007 — intervention group
Group type: EXPERIMENTAL
Intervention: General mailing of guidelines to clinicians
Number of subjects: 443
Study 12633007 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailing guidelines targeted to a patient starting treatment
Number of subjects: 443
Study 12633007 — intervention group
Group type: COMPARATOR
Intervention: No mailing of guidelines
Number of subjects: 443
Study 10695290 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (administered once or twice depending on prior vaccination status)
Number of subjects: 270
Study 10695290 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated control group
Number of subjects: 270
Study 8936398 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 14
Study 8936398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1585759 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitase (0.1%)
Number of subjects: 72
Study 1585759 — intervention group
Group type: COMPARATOR
Intervention: Micanol (0.1%)
Number of subjects: 72
Study 4091071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional self‐management program
Number of subjects: 11
Study 4091071 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction without nutritional self‐management program
Number of subjects: 11
Study 4091071 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control of caloric intake (fruit and vegetable)
Number of subjects: 11
Study 31178259 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (oral tablets), administered 12 and 2 hours preoperatively, and on the 2nd, 3rd, 4th, and 5th postoperative days
Number of subjects: 64
Study 31178259 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (oral tablets)
Number of subjects: 64
Study 31178259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 28986166 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100mg/day for 7 days
Number of subjects: 16
Study 28986166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 25862770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonophoresis with standard treatment (supervised exercises and cryotherapy)
Number of subjects: 88
Study 25862770 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis with standard treatment (supervised exercises and cryotherapy)
Number of subjects: 88
Study 25862770 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (supervised exercises and cryotherapy) with placebo iontophoresis and placebo ultrasonophoresis
Number of subjects: 88
Study 24672019 — intervention group
Group type: EXPERIMENTAL
Intervention: High craving trials
Number of subjects: 22
Study 24672019 — intervention group
Group type: EXPERIMENTAL
Intervention: Low craving trials
Number of subjects: 22
Study 24672019 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral task
Number of subjects: 22
Study 22207250 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (experimental group listening to recorded music)
Number of subjects: 62
Study 22207250 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 62
Study 20206790 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine 200 mg BID with food for 7 days and a morning dose on day 8
Number of subjects: 16
Study 17827960 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised toothbrushing once a day at school with 1,000 ppm fluoride toothpaste and a home support package encouraging twice-daily toothbrushing
Number of subjects: 428
Study 17827960 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (no brushing at school or home support package)
Number of subjects: 428
Study 15910950 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 20536
Study 15910950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20536